RUBINSTEIN JULIE sold $954K of ADPT

RUBINSTEIN JULIE (President and COO) sold 35,643 shares of Adaptive Biotechnologies Corp (ADPT) at an average of $26.78 ($25.78–$27.88, $0.95M total) across 7 trades over 2026-11-04 to 2026-11-06 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · RUBINSTEIN JULIE
Published Nov 7, 2026, 12:24 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 7, 2026, 12:28 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ADPT
Bearish
medium confidence
Mentioned
$ADPT
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ADPTBearishLow
01

Why it matters

A modest insider sell by a top executive may be interpreted as a slight negative signal, but the small amount limits market impact.

02

Market read

First‑report insider sale of under $1M; limited trading relevance but provides a data point for monitoring executive sentiment.

03

What to watch

Potential upcoming corporate actions or financing needs that prompted the sale are not disclosed.

Relevance 4/10Novelty 3/10Timing: post‑market filing

Background

SEC Form 4 filing discloses insider transactions, providing primary‑source information on executive share sales.

Company-level read

Ticker impact

$ADPTBearishMedium confidence
Context

President and COO Julie Rubinstein sold 35,643 shares for $954,442 via a 10b5-1 plan, reducing her stake to 377,802 shares.

Expected impact

likely modest pressure as the market prices in the insider sell

Evidence & confidence

Sale size is under $1M and the insider is a senior executive, which can be viewed as a minor negative signal but unlikely to move the stock significantly.

Market effects

none

none

none

Counterpoint

The sale could be routine under a pre‑arranged plan and not reflect any negative outlook, so the stock may remain stable.

Key entities

  • Adaptive Biotechnologies Corp

    US‑listed biotech company (ticker ADPT) whose President and COO sold shares.

  • Julie Rubinstein

    President and COO of Adaptive Biotechnologies, executing a 10b5‑1 sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ADPTHigh

Adaptive (ADPT) Q3 2026 Earnings Call Transcript

Adaptive (ADPT) raised its 2026 MRD revenue guidance due to strong clinical volumes and pharma revenue. Q3 saw 46% YOY growth in clinical testing volume, with 41% growth in clinical revenue. The company earned a milestone payment from Pfizer and is advancing its immune medicine separation process. Blood-based testing and community adoption of clonoSEQ increased significantly. U.S. ASP was $1,380 in Q3, with coverage gains in DLBCL and MCL.

$ADPTHigh

Adaptive Biotechnologies Corp (ADPT) Q3 2026 Earnings Call Highlights: First Profitable

Adaptive Biotechnologies (ADPT) reported Q3 2026 revenue of $83.9M, up 39% YoY, with GAAP net income of $2.8M. US ASP was $1,380, flat sequentially. The company expects no GAAP net income for Q4 or the full year. Challenges include Medicare payment structures and CMS rate uncertainties. Management remains confident in long-term pricing strategy and growth, citing favorable guidelines and market expansion.

$ADPTMedAI 8/10

Adaptive Biotechnologies Q3 Earnings Call Highlights

Adaptive Biotechnologies (ADPT) reported Q3 2026 revenue of $83.9M, up 39% YoY, with GAAP net income of $2.8M. The company raised its full-year MRD revenue outlook to $276M-$286M. Clinical testing volume increased 46% YoY, and clonoSEQ tests grew 10% sequentially. Adaptive expects 42% clinical volume growth for the year and is pursuing Medicare reimbursement updates.